Thermo Fisher and Charles River join Multiply Labs’ robotic consortium

By The Science Advisory Board staff writers

May 9, 2022 -- Multiply Labs has added Thermo Fisher Scientific and Charles River Laboratories to its robotic cell therapy manufacturing consortium, joining Cytiva and the University of California, San Francisco (UCSF) as members. This consortium promotes the automation and advancement of cell therapy manufacturing technologies.

A major purpose of Multiply Labs' consortium is to reduce the time and cost associated with the manual labor demands linked with cell therapy manufacturing. By automating these processes with robotic technologies and innovations, the consortium supports more efficient generation of cell therapies to provide patients with access to them sooner. As a result, the consortium demonstrates the beneficial capabilities of robotic integration into the drug manufacturing process.

Multiply Labs coordinates activities in the consortium related to robotics development, while UCSF is tasked with leading the cell manufacturing process as part of a research agreement. Regarding the roles of other consortium members, Cytiva uses its specialized bioreactor technology to manufacture CAR T-cell therapies. As new additions, Thermo Fisher will guide the automated operation of incubators and Charles River will focus on automating the quality control testing required as part of the manufacturing process. These institutions will all work toward the common goal of bringing these gene modified cell therapies to patients more quickly with the advantage of robotic technology.


Copyright © 2022 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.